Home › Research › Brain tissue and pathology
Amyloid deposition, hypometabolism, and longitudinal cognitive decline
Landau SM, Mintun MA, Joshi AD, Koeppe RA, Petersen RC, Aisen PS, Weiner MW, Jagust WJ et al.. Annals of neurology, 2012-10-01
Topic: Amyloid, tau and blood-test diagnosis
Objective Using data from the Alzheimer's Disease Neuroimaging Initiative (ADNI) population, we examined (1) cross-sectional relationships between amyloid deposition, hypometabolism, and cognition, and (2) associations between amyloid and hypometabolism measurements and longitudinal cognitive measurements. Methods We examined associations between mean cortical florbetapir uptake, mean (18) F-fluorodeoxyglucose-positron emission tomography (FDG-PET) within a set of predefined regions, and Alzhiemer's Disease Assessment Scale (ADAS-cog) performance in 426 ADNI participants (126 normal, 162 early mild cognitive impairment [EMCI], 85 late MCI [LMCI], 53 Alzheimer disease [AD] patients). For a subset of these (76 normal, 81 LMCI) we determined whether florbetapir and FDG-PET were associated with retrospective decline in longitudinal ADAS-cog measurements.
Key findings
- Methods We examined associations between mean cortical florbetapir uptake, mean (18) F-fluorodeoxyglucose-positron emission tomography (FDG-PET) within a set of predefined regions, and Alzhiemer's Disease Assessment Scale (ADAS-cog) performance in 426 ADNI participants (126 normal, 162 early mild cognitive impairment [EMCI], 85 late MCI [LMCI], 53 Alzheimer disease [AD] patients).
- For a subset of these (76 normal, 81 LMCI) we determined whether florbetapir and FDG-PET were associated with retrospective decline in longitudinal ADAS-cog measurements.
- Results Twenty-nine percent of normal subjects, 43% of EMCI patients, 62% of LMCI patients, and 77% of AD patients were categorized as florbetapir positive.
- Florbetapir was negatively associated with concurrent FDG and ADAS-cog in both MCI groups.
Why it matters
This 2012 study used Alzheimer's Disease Neuroimaging Initiative (ADNI) data from 426 people (126 cognitively normal, 162 early MCI, 85 late MCI, 53 Alzheimer's disease) to compare amyloid PET (florbetapir), brain glucose-use PET (FDG) and cognitive test scores. It reports that 29% of normal participants, 43% with early MCI, 62% with late MCI and 77% with Alzheimer's disease were classed as florbetapir positive, and that in both MCI groups florbetapir was 'negatively associated with concurrent FDG and ADAS-cog'. These are observational associations, not a treatment or prevention finding, and the text alzhub holds does not include the study's results on later cognitive decline.
Study details
- Study designcross-sectional
- Evidence strengthModerate
How this study scored 60/100
Published in a leading specialty journal, and it is a snapshot of people at one point in time. Scored zero for sample size, effect reported, studied in people and randomised / blinded because the record does not state it. We have no data on senior author's track record, so that was left out: it earned 58 of the 96 points we could judge it on, which is 60 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 9 / 10 | Tier 2 — leading specialty journal (Annals of neurology) |
| Journal's citation record | 3 / 4 | Annals of Neurology: journal h-index 437 (OpenAlex, 2026-10-29) |
| Study design | 4 / 12 | A snapshot of people at one point in time |
| Strength of evidence | 3 / 5 | Rated “moderate” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 1 / 5 | 2012 — within 20 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomised / blinded | 0 / 2 | No randomisation or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 6 / 7 | Cited 731 times (OpenAlex, 2026-10-10) |
| Citations per year | 4 / 5 | 45.7 citations a year over 16 year(s) since 2012 |
| Impact for its field and year | 5 / 6 | Cited 25.3× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 4 / 6 | Cited by 92 other studies in this library |
| Still being cited | 3 / 4 | Cited 163 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | — / 4 | Senior author's record not available — left out of this score |
| Institution's track record | 2 / 3 | University of Michigan: institution h-index 2,240 (OpenAlex) |
| Multi-centre collaboration | 2 / 3 | OpenAlex lists 9 institution(s) in 1 country |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 23109153) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Points | 58 / 96 | Scored on 19 of 20 parts. We have no data for the rest, so they are left out: 58 of the 96 points we could judge it on is 60 out of 100. |
| Total | 60 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
APA 7th
Landau, S. M., Mintun, M. A., Joshi, A. D., Koeppe, R. A., Petersen, R. C., Aisen, P. S., et al. (2012). Amyloid deposition, hypometabolism, and longitudinal cognitive decline. Annals of neurology. https://doi.org/10.1002/ana.23650
Vancouver
Landau SM, Mintun MA, Joshi AD, Koeppe RA, Petersen RC, Aisen PS, et al. Amyloid deposition, hypometabolism, and longitudinal cognitive decline. Annals of neurology. 2012. doi:10.1002/ana.23650. PMID: 23109153.
BibTeX
@article{landau2012-23109153,
author = {Landau, S. M. and Mintun, M. A. and Joshi, A. D. and Koeppe, R. A. and Petersen, R. C. and Aisen, P. S. and Weiner, M. W. and Jagust, W. J. and others},
title = {{Amyloid deposition, hypometabolism, and longitudinal cognitive decline}},
journal = {Annals of neurology},
year = {2012},
doi = {10.1002/ana.23650},
pmid = {23109153},
url = {https://doi.org/10.1002/ana.23650}
}
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 22.
Later studies that cite this one
92 studies in the alzhub library list this one in their references. Showing the 8 highest-scoring.
Related studies in Brain tissue and pathology
Also tagged “classification”
835 studies in the library carry the topic tag “classification”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 835 tagged studies.